INmune Bio
INMB
INMB
47 hedge funds and large institutions have $26M invested in INmune Bio in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
31% more funds holding
Funds holding: 36 → 47 (+11)
0.95% more ownership
Funds ownership: 11.84% → 12.79% (+0.95%)
Holders
47
Holding in Top 10
–
Calls
$645K
Puts
$367K
Top Buyers
| 1 | +$486K | |
| 2 | +$404K | |
| 3 | +$355K | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$331K |
| 5 |
BlackRock
New York
|
+$283K |
Top Sellers
| 1 | -$1.05M | |
| 2 | -$491K | |
| 3 | -$307K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$168K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$110K |